RWM
WINT

Rockwood Wealth Management’s Windtree Therapeutics WINT Stock Holding History

Rockwood Wealth Management’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$5.97K – 73
2022
Q4 		$5.97K Hold
1
– – ﹤0.01% 70
2022
Q3 		$10.5K Hold
1
– – ﹤0.01% 71
2022
Q2 		$12.6K Buy
+1
New +$29.5K 0.01% 72
2022
Q1 		– Hold
0
– – – 72
2021
Q4 		– Hold
0
– – – 117

Other funds holding WINT

TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Rockwood Wealth Management's WINT Position: Q1 2023 in Review

Rockwood Wealth Management sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 1 share — an estimated $5.97K sold.

Rockwood Wealth Management first reported a position in WINT in Q2 2022 and held it in 3 quarters. The position peaked at $12.6K in Q2 2022. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.

  • Rockwood Wealth Management reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockwood Wealth Management sold 1 Windtree Therapeutics share in Q1 2023, an estimated $5.97K.
  • Rockwood Wealth Management first reported a position in Windtree Therapeutics in Q2 2022 and held it in 3 quarters.
  • Rockwood Wealth Management's Windtree Therapeutics position peaked at $12.6K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.

Based on Rockwood Wealth Management's 13F filing for Q1 2023, filed 20 Jul 2023.